153 related articles for article (PubMed ID: 27324386)
41. Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial.
Vitolo U; Chiappella A; Franceschetti S; Carella AM; Baldi I; Inghirami G; Spina M; Pavone V; Ladetto M; Liberati AM; Molinari AL; Zinzani P; Salvi F; Fattori PP; Zaccaria A; Dreyling M; Botto B; Castellino A; Congiu A; Gaudiano M; Zanni M; Ciccone G; Gaidano G; Rossi G;
Lancet Oncol; 2014 Jun; 15(7):730-7. PubMed ID: 24831981
[TBL] [Abstract][Full Text] [Related]
42. Comparison of CHOP versus CIOP in good prognosis younger patients with histologically aggressive non-Hodgkin lymphoma.
Burton C; Smith P; Vaughan-Hudson G; Qian W; Hoskin P; Cunningham D; Hancock B; Linch D
Br J Haematol; 2005 Aug; 130(4):536-41. PubMed ID: 16098067
[TBL] [Abstract][Full Text] [Related]
43. Plasmablastic lymphoma transformation in a patient with Waldenström macroglobulinemia treated with ibrutinib.
Castillo JJ; LaMacchia J; Flynn CA; Sarosiek S; Pozdnyakova O; Treon SP
Br J Haematol; 2021 Nov; 195(3):466-468. PubMed ID: 34355802
[No Abstract] [Full Text] [Related]
44. Non-Hodgkin's lymphoma and acquired immune deficiency syndrome (AIDS). A case report.
Plemons JM; Benton E; Rankin KV
Tex Dent J; 2005 Jul; 122(7):658-64. PubMed ID: 16152890
[No Abstract] [Full Text] [Related]
45. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
[TBL] [Abstract][Full Text] [Related]
46. Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis of 8 patients.
Zimmermann H; Reinke P; Neuhaus R; Lehmkuhl H; Oertel S; Atta J; Planker M; Gärtner B; Lenze D; Anagnostopoulos I; Riess H; Trappe RU
Cancer; 2012 Oct; 118(19):4715-24. PubMed ID: 22392525
[TBL] [Abstract][Full Text] [Related]
47. AIDS-related Burkitt lymphoma--a heterogeneous disease?
Danilov AV; Pilichowska M; Danilova OV; Sprague KA
Leuk Res; 2008 Dec; 32(12):1939-41. PubMed ID: 18472158
[No Abstract] [Full Text] [Related]
48. Is cytotoxic chemotherapy for lymphoma currently feasible for patients in Malawi? A debate.
Crutchlow E; Miombe Y; Latham T
Malawi Med J; 2008 Dec; 20(4):120-3. PubMed ID: 19537393
[TBL] [Abstract][Full Text] [Related]
49. A randomized comparative study of cyclophosphamide, vincristine, doxorubicin, and prednisolone and cyclophosphamide, vincristine, mitoxantrone, and prednisolone regimens in the treatment of intermediate- and high-grade lymphoma with 8 years' follow-up.
Bezwoda WR; Rastogi RB
Semin Hematol; 1994 Apr; 31(2 Suppl 3):3. PubMed ID: 8073304
[No Abstract] [Full Text] [Related]
50. Bortezomib- and Lenalidomide-Based Treatment of Refractory Plasmablastic Lymphoma.
Ando K; Imaizumi Y; Kobayashi Y; Niino D; Hourai M; Sato S; Sawayama Y; Hata T; Ohshima K; Miyazaki Y
Oncol Res Treat; 2020; 43(3):112-116. PubMed ID: 31842017
[TBL] [Abstract][Full Text] [Related]
51. Burkitt lymphomas failing dose-adjusted R-EPOCH (DA-R-EPOCH).
Aurer I; Bašić-Kinda S; Radman I; Ilić I; Grah JJ
Ann Hematol; 2014 Jan; 93(1):177-8. PubMed ID: 23636314
[No Abstract] [Full Text] [Related]
52. The treatment of non-Hodgkin's lymphoma with mitoxantrone-containing regimens.
Sonneveld P
Semin Oncol; 1995 Feb; 22(1 Suppl 1):29-31. PubMed ID: 7863349
[No Abstract] [Full Text] [Related]
53. [HIV-related multiple non-Hodgkin lymphomas].
Gotoh M; Kitahara T; Iguchi T; Izumi M; Mukai K; Ohyashiki K
Rinsho Ketsueki; 2008 Nov; 49(11):1552-5. PubMed ID: 19047787
[TBL] [Abstract][Full Text] [Related]
54. [A comparative trial of C-novantrone OP(CNOP) vs C-adriamycin OP(CHOP) in the treatment of stage II-IV malignant lymphoma--the preliminary report].
Chuang MW; Tzeng CH; Chiou TJ; Chiu CF; Hsieh RK; Liu JH; Chen PM
Zhonghua Yi Xue Za Zhi (Taipei); 1988 Jan; 41(1):51-6. PubMed ID: 3167650
[No Abstract] [Full Text] [Related]
55. Human immunodeficiency virus-associated diffuse non-Hodgkin's lymphoma in Venezuelan patients: treatment with full-dose cyclophosphamide-doxorubicin-vincristine-prednisone without routine use of granulocyte-colony stimulating factor.
Hernàndez DE; Hernàndez AE
Eur J Cancer Care (Engl); 2006 Dec; 15(5):493-6. PubMed ID: 17177909
[TBL] [Abstract][Full Text] [Related]
56. Tumor melt: primary effusion lymphoma of the heart.
Kriekard P; Garcia JA; Nardi-Korver L; Krantz MJ
Am J Med; 2012 Sep; 125(9):e5-6. PubMed ID: 22682793
[No Abstract] [Full Text] [Related]
57. Reduced neurotoxicity with combined treatment of high-dose methotrexate, cyclophosphamide, doxorubicin, vincristine and prednisolone (M-CHOP) and deferred radiotherapy for primary central nervous system lymphoma.
Ichikawa T; Kurozumi K; Michiue H; Ishida J; Maeda Y; Kondo E; Kawasaki A; Date I
Clin Neurol Neurosurg; 2014 Dec; 127():106-11. PubMed ID: 25459253
[TBL] [Abstract][Full Text] [Related]
58. Dramatic treatment response of cutaneous plasmablastic lymphoma in an HIV patient: a case report.
Sakib SM; Sadler M
Clin Imaging; 2016; 40(6):1067-1069. PubMed ID: 27408991
[TBL] [Abstract][Full Text] [Related]
59. [A case of primary mucosa-associated lymphoid tissue lymphoma of the bladder regressed after rituximab in combination with CHOP chemotherapy].
Kakuta Y; Katoh T; Saitoh J; Yazawa K; Hosomi M; Itoh K
Hinyokika Kiyo; 2006 Dec; 52(12):951-4. PubMed ID: 17252980
[TBL] [Abstract][Full Text] [Related]
60. [Lymphomatoid granulomatosis treated with oral cyclophosphamide and prednisolone followed by CHOP].
Kure T; Uozumi K; Kikuchi A; Owatari S; Tsuji T; Haraguchi K; Tokunaga M; Tokunaga M; Suzuki S; Arima T
Nihon Naika Gakkai Zasshi; 2004 Apr; 93(4):774-6. PubMed ID: 15174726
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
